342 related articles for article (PubMed ID: 20528121)
21. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.
Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J
Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma cells deteriorate the biophysical properties of dendritic cells.
Zeng Z; Yao W; Xu X; Xu G; Long J; Wang X; Wen Z; Chien S
Cell Biochem Biophys; 2009; 55(1):33-43. PubMed ID: 19582594
[TBL] [Abstract][Full Text] [Related]
24. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Ormandy LA; Hillemann T; Wedemeyer H; Manns MP; Greten TF; Korangy F
Cancer Res; 2005 Mar; 65(6):2457-64. PubMed ID: 15781662
[TBL] [Abstract][Full Text] [Related]
25. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
26. Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape.
Wang H; Pan K; Xia JC
Ai Zheng; 2009 Feb; 28(2):184-7. PubMed ID: 19550135
[TBL] [Abstract][Full Text] [Related]
27. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
[TBL] [Abstract][Full Text] [Related]
28. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
[TBL] [Abstract][Full Text] [Related]
29. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
[TBL] [Abstract][Full Text] [Related]
30. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
31. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
32. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies.
Wirth TC
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):101-10. PubMed ID: 24410473
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
34. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma.
Behboudi S; Boswell S; Williams R
Liver Int; 2010 Apr; 30(4):521-6. PubMed ID: 20040052
[TBL] [Abstract][Full Text] [Related]
35. New therapies for hepatocellular carcinoma.
Avila MA; Berasain C; Sangro B; Prieto J
Oncogene; 2006 Jun; 25(27):3866-84. PubMed ID: 16799628
[TBL] [Abstract][Full Text] [Related]
36. [Changes in the immune function of dendritic cells (DC) derived from HBV-related hepatocellular carcinoma (HCC) patient's peripheral blood monocytes (PBMC) pulsed with tumor antigen].
Wong YQ; Qiu SJ; Tang ZY; Ye SL; Liu YK; Fan J; Sun RX; Zhao Y
Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):339-42. PubMed ID: 15918966
[TBL] [Abstract][Full Text] [Related]
37. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice.
Kayashima H; Toshima T; Okano S; Taketomi A; Harada N; Yamashita Y; Tomita Y; Shirabe K; Maehara Y
J Immunol; 2010 Jul; 185(1):698-708. PubMed ID: 20498356
[TBL] [Abstract][Full Text] [Related]
39. HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
Kikodze N; Mazmishvili K; Iobadze M; Rekhviashvili Kh; Nanava N; Pantsulaia I; Mizandari M; Janikashvili N; Chikovani T
Georgian Med News; 2015 Sep; (246):78-84. PubMed ID: 26355320
[TBL] [Abstract][Full Text] [Related]
40. Administration of dendritic cells in cancer nodules in hepatocellular carcinoma.
Kumagi T; Akbar SM; Horiike N; Kurose K; Hirooka M; Hiraoka A; Hiasa Y; Michitaka K; Onji M
Oncol Rep; 2005 Oct; 14(4):969-73. PubMed ID: 16142359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
